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efficacy of sunitinib in a mouse cancer model
Guo-Hua Deng, Jie Liu, Jie Zhang, Ying Wang, Xing-Chen Peng, Yu-Quan Wei and Yu Jiang*Abstract
Background: Sunitinib alone exhibits satisfactory efficacy in several mouse homografts and xenografts but
unsatisfactory efficacy in many kinds of solid tumors in clinic. Different from animals, receiving a diagnosis of cancer
impacts chronic stress on patients. Here, we examine whether norepinephrine (NE), one of the most potent stress
related hormones, leads to the difference in the efficacy of sunitinib between clinical and preclinical trials.
Methods: The influence of NE on mouse melanoma B16F1 cells under sunitinib was evaluated in vitro and in vivo.
The β-AR/cAMP/PKA (β-adrenoceptor/cyclic adenosine monophosphate/protein kinase A) signaling pathway was
also evaluated in human lung adenocarcinoma cells.
Results: We found that NE upregulated the expression of VEGF, IL-8 and IL-6 in vitro and stimulated tumor growth
in vivo, which was mediated by β-AR/cAMP/PKA signaling pathway and could be inhibited by propranolol, a
β-blocker for hypertension for decades.
Conclusions: This research indicates exogenous norepinephrine attenuates the efficacy of sunitinib, and a
combination of sunitinib and propranolol might be suggested as a new strategy in solid tumor in clinic.
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Psychosocial factors including chronic stress, depression,
dejection, and lack of social support have been proved
risk factors for cancer occurrence and progression by
psychological and epidemiological studies [1-4]. It is well
known that chronic stress impacts on immune system,
neuroendocrine system, lymphatic and hematopoietic sys-
tem. Stress inhibits the immune response ability in
antigen-specific T-cells and natural killer cells while sti-
mulates the secretion of proinflammatory cytokines, such
as IL-1, IL-2, IL-6, IL-8, IL-11 and TNF-α, which were
regarded as co-factors for modulating the growth and pro-
gression of tumor [5,6]. Recent studies reported that
chronic stress can also immediately affect the growth,
development and metastasis of malignant tumors via hor-
mone receptors on tumor cells [7-10].
In mammals under stress, an increased level of stress-
related hormone (SRH) can be induced by the acti-
vation of the hypothalamic-pituitary-adrenal and the* Correspondence: jiangyu1973@hotmail.com
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unless otherwise stated.sympathetic-adrenal medullary axes. Activation by stress
on sympathetic nervous system results in the release of
catecholamines from the adrenal medulla and sympathetic
nerve terminals [6,10]. Catecholamines consist of several
kinds of substances such as dopamine, histamine, sero-
tonin, epinephrine and norepinephrine (NE). The last one
is regarded as the most potential SRH related to tumors
in mammals [10,11]. As ligands, catecholamines can bind
adrenergic receptors (ARs) coupled with G-protein which
can be classified as several subtypes such as α1, α2, β1, β2
and β3 ARs. Many types of ARs locate on tumor cells,
providing the theory that chronic stress impacts on the
progression of cancer. Furthermore, the effect of stress
could be mimicked with NE or β2-AR agonists, and abol-
ished with surgical sympathetic denervation, β-AR antago-
nists or knocking down β2-AR gene by small interfering
RNA [6,10,12].
It is accepted that a solid tumor can not progress
without angiogenesis. VEGF, one of the most important
angiogenic factors, can recruit and induce endothelial
cells to proliferate and migrate, thereby starting the crit-
ical step of tumor expansion. Previous studies havetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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MMP expression levels in some kinds of tumor cells
in vitro such as melanoma, breast cancer, colon cancer,
prostate cancer, ovary cancer, pancreatic cancer and na-
sopharynx cancer. Besides, migration of cancer cells can
be stimulated by NE, which can be blocked by nonselec-
tive β-AR antagonist, propranolol [7-9,13-18]. In mouse
models in vivo, chronic stress stimulates the growth, pro-
gression and metastasis of tumors, which can also be
inhibited by propranolol [13-15,19]. The clinical research
reported that propranolol lowered the rate of breast
cancer-specific mortality, cancer recurrence and distant
metastasis, thus improved relapse-free survival and cancer
specific survival [20-22].
Tumor angiogenesis plays a key role in development of
solid tumors. Sunitinib, one kind of anti-angiogenic drugs,
is a tyrosine kinase inhibitor with the ability of blocking
VEGFR1, VEGFR2, VEGFR3, PDGFRα, PDGFRβ, c-Kit and
RET. It can induce tumor cell death and inhibit tumor
proliferation and vascularization [23-25]. However, in clinic,
treatment with sunitinib alone is of poor curative effect
or even inefficacious for many types of solid tumors.
On the contrary, sunitinib exhibits satisfactory efficacy
in mouse homografts of melanoma, Lewis lung cancer,
renal cancer and colon cancer, and xenografts of human
colorectal cancer in vivo [24,26-28]. Additionally, mo-
notherapy with anti-angiogenic drugs including endo-
statin and bevacizumab also shows the discrepancy
between clinical and preclinical results [29,30]. Thus
the question should be presented: Why does the differ-
ence of the curative response between the human and
animal occur?
Different from tumor-bearing mice, receiving a diag-
nosis of malignancy and battling with chronic uncertain-
ties as regards treatment, progression, recurrence, and
mortality is a major chronic stressor imaginable for pa-
tients with cancer. Given the impact of chronic stress on
a cancer patient, the confluence of the psychological and
physical discomfort places the patient at high risk for
the occurrence of stress-induced behavioral alterations
which usually presents depression, anxiety, sadness, fear
and hopelessness [4,11,31,32]. We reported previously
that 39.5% of cancer patients were unwilling to realize
the diagnosis of cancer, 63.0% were burdened with men-
tal stress and 33.0% considered the impact of mental
stress above that of somatic symptoms [33].
We hypothesize that the discrepancy of the efficacy of
anti-angiogenic drugs between clinical and preclinical
results is caused by chronic stress, which has not been
yet identified. So in this research, the goal is to investi-
gate whether NE, one of the most potent stress related
hormones, can attenuate the efficacy of sunitinib in a
mouse model and whether this effect can be blocked by
propranolol.Materials and methods
Cell culture
The murine melanoma B16F1 cells and human lung
adenocarcinoma A549 cells, kind gifts from State Key
Laboratory of Biotherapy (Sichuan University, Chengdu),
were authenticated by the supplier [29] and cultured in
RPMI 1640 complete medium containing 10% fetal bovine
serum (FBS), 100 U/mL penicillin, and 100 μg/mL strepto-
mycin at 37°C with 5% CO2 in humidified atmosphere.
Reagents
NE, 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium
bromide (MTT), dimethylsulfoxide (DMSO), isoprote
renol, dobutamine and terbutaline were purchased from
Sigma (St. Louis, MO, USA); propranolol and 8-CPT
from Enzo (Germany); forskolin from Biovision (USA);
H-89 and myristoylated PKI from Calbiochem (USA);
sunitinib from Pfizer (USA); RNAiso plus and One Step
SYBR® PrimeScript™ RT-PCR Kit from TaKaRa (Japan).
In vitro cell proliferation assays for measuring the IC50
(half maximal inhibitory concentration) of sunitinib in
B16F1 cells
B16F1 cells were harvested and seeded in 96-well plates
(5,000 cells/200 μL complete medium/ well). After 24 hours
incubation, the cells were exposed to various concentra-
tions (0–100 μM, each concentration had six replicate
wells) of sunitinib for 48 h. Following sunitinib treatment,
20 μL of 5 mg/mL MTT was added to each well and incu-
bated at 37°C for 4 hours. The plates were centrifuged, the
supernatants were carefully discarded and formazan crys-
tals were dissolved in 150 μL DMSO. At last, the light ab-
sorbance at 490 nm was determined in a luminescence
plate reader (PerkinElmer, USA) according to the manufac-
turer’s instructions.
Evaluation of the influence of NE on mRNA and protein
expression in vitro
B16F1 and A549 cells were dispensed in six-well culture
plates (2 × 105/well). After incubation overnight, 2 mL
complete RPMI 1640 medium was replaced by serum-
free medium for 24 hours to make the cells adapt
serum-starvation. Then cells were incubated in 2 mL
renewed serum-free medium containing 0, 0.1, 1, 10 μM
NE or 10 μM NE +10 μM propranolol (propranolol was
added 30 minutes prior to NE). Culture supernatants
were gathered and cells were homogenized in RNAiso
plus at different time points designed for detection by
ELISA (3, 6, 12 and 24 hours) and real-time PCR (1, 2, 3
and 4 hours), respectively. In addition, we evaluated the
influence of 10 μM NE in B16F1 cells treated with suni-
tinib at the concentration equal to IC50 (sunitinib was
added 30 minutes following NE).
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pathway
A recent study identified that the β2-AR/cAMP/PKA
signaling pathway mediated the up-regulation of VEGF
by NE on human ovarian cancer cells [9]. Here we tested
the role of this pathway on A549 cells. First, 10 μΜ
α-AR antagonist phentolamine and 10 μΜ β-AR antag-
onist propranolol were added into the cell cultures
30 minutes before adding 10 μM NE in order to assess
the role of AR subtypes (α-AR VS β-AR). Second, A549
cells were incubated in serum-free medium containing
10 μΜ β-AR agonist isoproterenol, 10 μΜ β1-AR agonist
dobutamine, 10 μΜ β2-AR agonist terbutaline, 100 μΜ
selective activator of the cAMP receptor 8-CPT, 10 μΜ
adenylate cyclase agonist forskolin, 100 μΜ cAMP-
dependent protein kinase inhibitor H-89 or 10 μΜ
myristoylated protein kinase inhibitor PKI. Similar to
propranolol, H-89 or PKI was added 30 minutes before
the addition of 10 μM NE [17]. Culture supernatants
were harvested 6 hours after treatment for ELISA and
cells were homogenized in RNAiso plus 2 hours after
treatment for RT-PCR. In order to evaluate the prolifer-
ation and migration of A549 cells under the inhibitors
PKI and H-89, MTT assay and scratch wound healing
assay were performed as previously described [34-36].
In vivo tumor model
C57BL6 female mice (4–6 weeks old) were purchased
from the Laboratory Animal Center of Sichuan Univer-
sity. Male mice should be excluded for possible stress
from mates in the cage. The animal experiments with
the C57BL6 mice were consistent with protocols ap-
proved by the Institutional Animal Care and Treatment
Committee of Sichuan University. The mice were main-
tained under pathogen-free conditions with food and
water ad libitum, on 12 h/12 h day/night cycle, a
temperature of 21–25°C, three mice per cage.
B16F1 cells were trypsinized, centrifuged and then re-
suspended in serum-free medium. For implantation, tu-
mors cells were subcutaneously inoculated in the right
flanks of mice (5 × 105 cells per mouse). Tumor mea-
surements were made periodically with manual calipers
every three days, and tumor volume was calculated ap-
plying the formula: π/6 × length × width2. At the end of
the test, mice were sacrificed and tumors were excised,
weighed and photographed. The serum from mice was
harvested.
Establishment of chronic stress in vivo and treatment with
sunitinib
Eight days after inoculation when the tumors reached an
average diameter of 5 mm, mice were randomly assigned
to four groups each consisting of six mice. The mice
were narcotized by chloral hydrate i.p. (4%, 10 mL/kg)and then microosmotic pumps (Alzet model 1004, Durect,
Cupertino, CA) were implanted subcutaneously on the left
back of the mice for the establishment of chronic stress.
The microosmotic pumps implanted in the body could
keep functional and pump drugs contained continuously
for up to 4 weeks. The pumps were filled with 100 μL nor-
mal saline containing 56 mM NE, 56 mM propranolol or
both of them at a dose of 1 μmol/100 g/day [14]. Ascorbic
acid (0.2%) was added as a preservative into every pump.
The pumps full of just normal saline and ascorbic acid
were used in the control group. The initiation of treatment
with sunitinib by oral gavage (80 mg/kg/day [27]) was on
the next day. The animals were sacrificed after 14 days of
treatment.
ELISA
The concentrations of VEGF, IL-8 and IL-6 proteins in
culture supernatants or serum were detected using
mouse or human ELISA Kits (Neobioscience, Beijing)
following the manufacturer’s protocol. The light absorb-
ance at 450 nm was read in a luminescence plate reader
(PerkinElmer, USA). The values of concentrations were
calculated by interpolation from a standard curve. Each
experiment was repeated at least three times in duplicate.
Immunohistochemistry for CD31, VEGF, β1-AR and β2-AR
Immunohistochemical studies were performed as pre-
viously described [26] using antibodies against CD31
(rat antimouse monoclonal antibody, diluted 1:300; BD
Pharmingen, San Diego, CA, USA), VEGF (rabbit anti-
mouse polyclonal antibody, diluted 1:200; Bioss Biotechol-
ogy, Beijng), β1-AR & β2-AR (rabbit antimouse polyclonal
antibody, diluted 1:300; Bioss Biotechology, Beijng).
CD31 was stained on the frozen sections from B16F1 tu-
mors for measuring microvessel density (MVD), VEGF on
the formalin-fixed and paraffin-embedded sections from
B16F1 tumors for comparing the expression levels among
four groups and β1-AR and β2-AR on the slides of B16F1
cells for detecting the status of β-ARs in cells. Phosphate
buffered saline was used instead of the primary antibody
for negative controls.
Assessment of microvessel density
MVD was assessed by choosing three areas with thickest
microvessel distribution (hot spot) according to immu-
noreactivity for CD31 at low microscopic magnification
(40 ×) and then counting the number of immunoreactive
endothelial cells and microvessels from three 200 × high
power fields in hot pot areas [37,38].
RT-PCR analysis
The assessment of VEGF, IL-8 and IL-6 gene expression
was conducted using semiquantitative real-time reverse
transcription-PCR (RT-PCR). Total RNA from A549 cells
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traction protocols. Then the RNA was separated by 1%
agarose gel electrophoresis and visualized by golden view
to test the quality and integrity of RNA samples using the
Gel Doc image system (Bio-Rad, Hercules, CA, USA).
RT-PCR was conducted using One Step SYBR® Prime-
Script™ RT-PCR Kit (Perfect Real Time) and amplified
with CFX 96™ Real-Time System in C1000™ Thermal
Cycler (Bio-Rad, USA). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was applied as an internal
positive control. The primers in this study were as
follows: GAPDH: sense 5′- ACCACAGTCCATGCCA
TCAC -3′, antisense 5′- TCCACCACCCTGTTGCTG
TA -3′; VEGF: sense 5′- TGGATCCATGAACTTTC
TGCTGTC -3′, antisense 5′- TCACCGCCTTGGCT
TGTCACAT -3′; IL-8: sense 5′-CTTTGTCCATTCC-
CACTTCTGA-3′, antisense 5′-TCCCTAACGGTTG
CCTTTGTA T-3′; IL-6: sense 5′- ATGAACTCCT
TCTCCACAAGCGC -3′, antisense 5′- GAAGAGCC
CTCAGGCTGGACTG -3′ [12,39-41]. The PCR cycler
condition was according to the recommendations in
the manufacturer’s instructions. Reactions were per-
formed in a 25-μL volume and each sample was run at
least in duplicate. The levels of expression of VEGF,
IL-8, and IL-6 mRNA in each sample were normalized
to the GAPDH mRNA level. The relative expression of
VEGF, IL-8, and IL-6 mRNA was calculated applying
the comparative CT method [18,39].
Statistical analysis
The data are expressed as the mean ± SD. Changes in
protein and mRNA levels of VEGF, IL-8 and IL-6, the
averaged tumor volume and weight were calculated by
one way analysis of variance (ANOVA) with an LSD
post-hoc test and an unpaired student’ t test using SPSS,
version 15.0 (SPSS, Chicago, IL). A p value less than 0.05
was considered as statistically significant.
Results
NE upregulates VEGF, IL-8, and IL-6 protein levels in cul-
ture supernatants of B16F1 (with or without sunitinib)
and A549 cells, which can be blocked by propranolol
A NE dose-dependent and time-dependent increase in
VEGF, IL-8 and IL-6 protein levels in culture supernatants
of both B16F1 and A549 cells with a peak increase at the
6 hours time point and 10 μM concentration, which could
be blocked by 10 μM propranolol (Figure 1A-F). In A549
cells, treatment with 10 μM NE for 6 h caused a remark-
able increase to 242.79 ± 19.86%, 331.56 ± 24.41% and
685.85 ± 34.72% (P < 0.001) of control levels for VEGF,
IL-8 and IL-6 protein levels, respectively (Figure 1A-C).
Likewise, in B16F1 cells, VEGF, IL-8 and IL-6 protein
levels arrived at 185.15 ± 12.13%, 301.35 ± 24.98% and
294.40 ± 23.17% (P < 0.001) of control levels in response toexposure to 10 μM NE for 6 hours (Figure 1D-F). Overall,
the increase could be most seen in both two cells at the
NE concentration ranging from 0.1 to 10 μM since 3 hours
after treatment. However, as time went on, the extent of
the increase reduced 6 hours later.
In addition, the IC50 of sunitinib in B16F1 cells mea-
sured by cell proliferation assays was 3.35 μM. The re-
sults about B16F1 cells treated with sunitinib at the
concentration equal to IC50 indicated that NE could also
upregulate VEGF, IL-8, and IL-6 proteins with a peak in-
crease at the 6 hours time, which could also be blocked
by 10 μM propranolol (Figure 1G-I).
NE promotes tumor growth in the murine B16F1 model
under the treatment of sunitinib and can be blocked by
propranolol
Our results showed that NE speeded up the tumor growth
rate in the B16F1 model treated with sunitinib. Similar
with the results in vitro as above, the effect of NE could
be blocked by propranolol (P < 0.05) (Figure 2A-E). NE
increased the tumor weight by 51.65% compared with
normal saline (0.99 ± 0.28 g VS 0.65 ± 0.27 g, P = 0.014)
and 79.22% compared with the combination of NE and
propranolol (0.99 ± 0.28 g VS 0.55 ± 0.08 g, P = 0.002)
(Figure 2D).
As shown in Figure 2F, VEGF, IL-8 and IL-6 protein
levels tested by the ELISA assay were upregulated by NE
in the serum from the B16F1 model, which could be
blocked by propranolol. NE increased VEGF, IL-8 and
IL-6 protein levels by 155.77%, 417.77% and 586.21%
compared with normal saline, respectively (P < 0.001).
NE stimulates tumor angiogenesis in the B16F1 model
treated with sunitinib
Immunohistochemical staining for VEGF on the formalin-
fixed and paraffin-embedded sections showed a much
stronger staining in the tumors of the group stimulated by
NE than the other three groups (normal saline, propran-
olol and NE + propranolol) (Figure 3A). There is no brown
or yellow staining in negative control slides for VEGF
wherein no primary antibodies were used (Figure 3D).
Similar to VEGF, the significant increase in MVD,
detected by immunohistochemical staining for CD31 on
frozen sections, occurred in the tumors of the mice
treated with sunitinib and stimulated by NE (P < 0.05)
(Figure 3B-C).
Beta1-AR and β2-AR are expressed in B16F1 cells
Immunohistochemical staining for β1-AR and β2-AR on
the slides of B16F1 cells was utilized to evaluate the sta-
tus of β-AR via which NE affected cells. The results
showed strong β1 and β2-AR immunoreactivivty located
in the cytoplasma (Figure 3E, F, respectively). The stain-
ing was invisible in negative control slides (not shown).
Figure 1 Effect of NE in vitro (with or without sunitinib). VEGF, IL-8 and IL-6 protein levels in culture supernatants by A549 (A, B, and C) and
B16F1 (D, E and F) cells were measured after incubation with 0 (CON), 0.1, 1, 10 μM NE and 10 μM NE + 10 μM PROP for 3, 6, 12 and 24 hours.
The levels of VEGF, IL-8, and IL-6 protein in B16F1 (G, H and I) cells incubated with 3.35 μM SUN alone (CON), 3.35 μM SUN + 10 μM NE, 3.35 μM
SUN+ 10 μM PROP and 3.35 μM SUN+ 10 μM NE + 10 μM PROP for 6 hours were also detected. Data are represented as percentage of the control
well, which was set as 100% in each experimental series. All bars represent the mean ± SD of at least three experiments performed in duplicate. CON,
control. SUN, sunitinib. ND, not detectable. *, P ≤ 0.05; **, P ≤ 0.001.
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A549 cells
Although the up-regulation of VEGF, IL-8, and IL-6
protein levels by NE was described as above, we
assessed the effect of NE on the expression of these
three genes to further clarify the mechanism concern-
ing the modulation of these three proteins in A549
cells. The results indicated that the levels of VEGF,
IL-8, and IL-6 mRNA increased rapidly with a peak
after 2 hours of treatment and decreased gradually there-
after in A549 cells exposed to 10 μM NE (Figure 4A-C).Beta-AR/cAMP/PKA signaling pathway contributes to the
NE effect in A549 cells
For determining whether β-AR mediated the NE effect,
phentolamine (α-AR antagonist) was used here to contrast
with propranolol. We observed that, opposite to propran-
olol, phentolamine could not abrogate the NE-induced in-
crease of VEGF, IL-8, and IL-6 mRNA levels in A549 cells
(Figure 4D).
Isoproterenol (nonselective β-AR agonist), dobutamine
(selective β1-AR agonist) and terbutaline (selective β2-AR
agonist) upregulated VEGF, IL-8, and IL-6 mRNA levels,
Figure 2 NE attenuates the efficacy of sunitinib in vivo. A) Preoperative preparation for implanting micro-osmotic pumps which should
soaked in normal saline for at least 48 hours at 37°C. B) The pumps were implanted subcutaneously on the left back of the mice. C) The photograph of
the tumors excised from all mice in 4 groups in B16F1 models. D) The bar chart showing the weight of the tumors. E) The line chart showing tumor
growth curves. F) VEGF, IL-8 and IL-6 protein levels measured by ELISA in the serum from the mice in B16F1 models. Data are represented
as percentage of the control (SUN without NE or PROP). All bars represent the mean ± SD. SUN, sunitinib. PROP, propranolol. *, P ≤ 0.05;
**, P ≤ 0.001.
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the NE-dependent effect (Figure 4E-G). Moreover,
comparing with β1-AR, β2-AR played a key role as a
mediator special for the NE-induced stimulation of
VEGF and IL-8 gene expression in A549 cells because
terbutaline had a higher degree of up-regulation than
dobutamine. Additionally, 8-CPT and forskolin (cAMP
analogs) both raised VEGF, IL-8, and IL-6 mRNA levels
implicating cAMP as a mediator. Lastly, H-89 (PKA in-
hibitor) nearly checked the effect of NE which could be
just partially inhibited by PKI.
To further identify the role of β-AR/cAMP/PKA signal-
ing pathway in NE-treated A549 cells, the changes in
VEGF, IL-8, and IL-6 protein levels tested by the ELISA
assay related to mRNA levels as above were also analyzed.We observed similar changes in VEGF, IL-8, and IL-6 pro-
tein levels with their mRNA levels (Figure 5A-D).
We also evaluated the proliferation and migration of
A549 cells under the inhibitors PKI and H-89. The re-
sults showed that, different from PKI, H-89 inhibited the
proliferation (Figure 6A) and migration (Figure 6B-C) of
A549 cells. These results were consistent with the pro-
tein and gene levels of VEGF, IL-8 and IL-6 of A549 cells
under PKI and H-89.
Discussion
In this study we showed that NE spurred tumor growth
in the murine melanoma model treated with sunitinib by
gavage in vivo and could be inhibited by propranolol.
We also identified that NE upregulated VEGF, IL-8, and
Figure 3 NE promotes angiogenesis in vivo. A) Representative photographs of the B16F1 tumor sections examined by immunohistochemical
staining for VEGF (× 200 magnification). B) Immunohistochemical staining for CD31 (× 200 magnification). C) The bar chart showing MVD calculated
by CD31 immunoreactivity. Each bar represents the average vessel number of each group, expressed as the mean ± SD. *, P≤ 0.05. D) The photograph
of immunohistochemical staining in negative control slides for VEGF. E) Immunohistochemical staining for β1-AR on the slides of B16F1 cells (× 200
magnification). F) Immunohistochemical staining for β2-AR (× 200 magnification).
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sence of the treatment with sunitinib at the concentra-
tion equal to IC50, which was blocked by propranolol. In
addition, NE-dependent up-regulation in both protein
and gene levels of VEGF, IL-8, and IL-6 was observed
in human lung adenocarcinoma cells in which β-AR/
cAMP/PKA signaling pathway was proved as the im-
portant mechanism. Chronic stress has been acknowl-
edged as an important factor affecting patients with
cancer and the effect of chronic stress may be persistent
during the process from diagnosis for cancer to death of
cancer. The activation on sympathetic nervous system
by stress gives rise to the increased level of catechol-
amines resulting in several biological effects via ARs
such as VEGF-caused stimulation in angiogenesis, raised
levels of cytokines including IL-8 and IL-6 [42]. These
effects were also proved in our study and found as at
least a part of factors attenuating the efficacy of sunitinib
in preclinical models.
In order to mimic chronic stress in patients, a wide
variety of stress models in animals were established, e.g.
addition of corticosterone to drinking water, transfer to
a cold room at 4°C, subcutaneously administration with
NE or β2-AR agonists, restraint procedure using open-
ended Plexiglas cylindrical restrainers, social defeat,social isolation, unpredictable chronic mild stress, re-
peated social defeat, subcutaneous microosmotic pumps
containing NE [12,43-49]. However, some of stress mo-
dels aforementioned have limitations more or less and
thus induce unpredictable impacts on tests in vivo. For
addition of corticosterone to drinking water, this test
might not control the volume of water drunk by animals
and thus the reliable uptake of corticosterone can not
be evaluated especially when uptake of water was in-
terrupted by the disorders in animals such as a heavy
tumor burden [49]. For the restraint test, it was found
in our laboratory that mice would adapt the open-ended
Plexiglas cylindrical restrainers in the later stage. So the
restraint test might not sustain enough stress if the ob-
servation in a test in vivo should be kept for a long time
[45]. Seeing that microosmotic pumps (1004 type) are
of the ability of pumping drugs contained incessantly
for up to 4 weeks and exhibit reliable effects in mouse
models, the pumps were taken into account in our re-
search to deal with the short half life period of NE. It is
well known that in clinic patients are under chronic
stress after diagnosed with cancer prior to treatment.
Thereby, in order to mimic patients in clinic as possible,
sunitinib was administrated 30 minutes following NE in
tests in vitro, and treatment with sunitinib was started
Figure 4 Evaluation of β-AR/cAMP/PKA signaling pathway by RT-PCR. The NE-dependent stimulation of VEGF (A), IL-8 (B), and IL-6 (C)
mRNA levels with a peak at 2 hours was observed in treatment of A549 cells with 10 μM NE (A, B, and C). This effect could not be blocked by
phentolamine (PHEN) (D). Representative results of VEGF (E), IL-8 (F), and IL-6 (G) mRNA levels treated with NE, isoproterenol (ISO), dobutamine
(DOB), terbutaline (TER), 8-CPT, forskolin (FOR), NE + H89 or NE + PKI for 2 hours. Values are presented as percent of untreated control levels. Each
bar represents the mean ± SD. ND, not detectable. *, P≤ 0.05; **, P≤ 0.001.
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tests in vivo.
Tumor neovascularization or angiogenesis is closely
related with proangiogenic factors such as VEGF, IL-8,
IL-6, TGF and TNF released by tumor cells and immune
cells. In analogy to tumors cells, lymphocytes and mac-
rophages in the tumor microenviroment also express β-
ARs triggered by NE with the following increased levels
of VEGF, IL-8, and IL-6 [50-53]. The NE-induced up-
regulation of VEGF, IL-8, and IL-6 protein levels was found
in a number of human cancer cell lines such as colon can-
cer, nasopharyngeal cancer, ovarian cancer, prostate cancer
and melanoma [7,8,13,17,18]. This effect of NE was identi-
fied in murine melanoma B16F1 cells and human lung
adenocarcinoma A549 cells in our study. In addition, this
phenomenon was also observed in murine colon cancer
CT26 cells and some human cancer cells (e.g., nasopharyn-
geal cancer HNE1 & CNE2 cells, breast cancer MDA-MB-
231 & MDA-MB-468 cells and colon cancer HT-29 &
SW480 cells) in other studies in our laboratory (unpub-
lished date not shown). However, to our knowledge, noth-
ing is known of the influence of NE in cancer cells treated
with sunitinib in vitro. Our date indicated that, in
B16F1 cells treated with sunitinib at IC50 concentration,
NE also increased VEGF, IL-8, and IL-6 protein expressionin culture supernatants, which could be inhibited by pro-
pranolol. This result offered at least a mechanism for the
difference in the efficacy of sunitinib between clinical and
preclinical trials. It should be considered if sunitinib acts
via some of its targets on B16 cells. Previous studies re-
ported that B16 cells did not express VEGFR1, VEGFR2,
VEGFR3 [54,55], PDGFRα and PDGFRβ [56] but no more
than 10% of B16 cells expressed c-Kit [57]. Whether su-
nitinib acts on B16 cells through the c-Kit target re-
mains to be investigated in the further study. Chronic
stress has been demonstrated to promote development
and progression of tumors in several human cancer cells
in xenografts including prostate cancer, ovarian cancer
and breast cancer [9,13,15,46,58], whereas no date re-
garding the influence of chronic stress in cancer models
under sunitinib in vivo has been reported so far. This
study showed that consecutive NE pumped stimulated
the growth of primary tumor in a mouse melanoma
model and could be blocked by propranolol. This result
provided a piece of evidence for the discrepancy in
the efficacy of sunitinib between clinical and preclinical
trials and was consistent with the results in the other
studies in our laboratory (mouse colon cancer CT26
homograft and human colon cancer SW480 and HT-29
xenografts, unpublished date not shown).
Figure 5 Evaluation of β-AR/cAMP/PKA signaling pathway by ELISA. The NE-dependent stimulation of VEGF, IL-8, and IL-6 protein levels
could not be blocked by phentolamine (PHEN) (A). Representative results of VEGF (B), IL-8 (C), and IL-6 (D) protein levels treated with NE, isoproterenol
(ISO), dobutamine (DOB), terbutaline (TER), 8-CPT, forskolin (FOR), NE + H89 or NE + PKI for 6 hours. Values are presented as percent of untreated control
levels. Each bar represents the mean ± SD. *, P≤ 0.05; **, P≤ 0.001.
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we analysed the immunoreactivity for VEGF and CD31,
counted the MVD and measured the protein levels of
VEGF, IL-8 and IL-6 in mouse serums. As expected,
in accordance with the results in vivo as mentioned in
the previous paragraph, chronic stress promoted angio-
genesis and neovascularization in B16F1 tumors, thus
withstood the anti-angiogenic treatment of sunitinib.
Interestingly, relatively low VEGF expression was found
in tumor and endothelial cells while stronger VEGF
expression usually found in peri-necrotic tumors cells
mainly by reason of hypoxia as reported in the other
study [59]. In clinic, the serum levels of VEGF, IL-8
and IL-6 have been suggested as potentially predictive
markers for survival in cancer patients under sunitinib.
Bauerschlag et al. [60] found that 18 cases with a decrease
in VEGF serum concentration out of 29 ovarian cancer
patients with sunitinib therapy had a longer progression-
free survival (PFS) compared to 11 cases with an increase
in VEGF serum concentration (10.5 VS 2.9 months). Like-
wise, the lower serum VEGF level was reported to be
associated with longer PFS and objective response rate
in patients under sunitinib with bevacizumab-refractory
metastatic renal cancer [61]. Bellmunt et al. [62] announced
that the low serum IL-8 level was related to long median
time to progression in urothelial cancer patients receiving
sunitinib as first-line treatment. Comparing with healthy
donors, an increased level of IL-8 was detected in serums
from medullary thyroid carcinoma patients with distant
metastases [63]. Zhu et al. [64] reported that advancedhepatocellular carcinoma patients with high serum levels of
IL-8 and IL-6 were of high mortality and rapid tumor pro-
gression after sunitinib. On the other hand, patients with a
decrease level of IL-6 had better PFS and overall survival.
Additionally, during sunitinib treatment, a more elevated
IL-6 level was in correspondence with higher hazard of
mortality or immediate progression.
ARs are a family of G protein-coupled receptors, also
called serpentine receptors whose ligands mainly include
chemokines and neurotransmitters [31]. Since the expres-
sion of β-ARs was observed in human lung adenocar-
cinoma A549 cells [65,66], only an immunohistochemical
analysis for β-ARs in B16F1 cells was carried out. Hegener
et al. [65] also found that the internalization and en-
docytosis of β2-AR in A549 cells were stimulated by
terbutaline (selective β2-AR agonist) and forskolin (cAMP
analogs), whereas blocked by propranolol. In our study,
the strong expression of β-ARs located in the cytoplasma
and there was no difference of staining intensity between
β1-AR and β2-AR discerned with naked eyes. This finding
in our study provided the basis for following research on
the β-AR/cAMP/PKA pathway in B16F1 cells. Conside-
ring ARs play a key role mediating the effect on tumors
induced by chronic stress and endow tumor cells the po-
tential to respond to neurotransmitters, few scholars sug-
gest the receptor-based interference of intracellular ARs
signaling pathway as a new approach to resist this effect
[9,42,67,68]. Powe et al. [69] found, in breast cancer, β2-
AR strongly immunoreactive in cases with a luminal
phenotype and good clinic outcome while α1b-AR and
Figure 6 The proliferation and migration of A549 cells under PKI and H-89. MTT assay showed that H-89 inhibited the proliferation of A549
cells (A) and wound healing assay showed H-89 lowered the migration of A549 cells (B and C). CON, control. *, P≤ 0.05.
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http://www.jeccr.com/content/33/1/21α2c-AR over-expressed in basal-like phenotypes of poor
prognosis. So ARs might be supposed to be potential
predictors for survival and probable indicators for tar-
geted therapy with AR blockers.
In the present research, it was approved in A549 cells
that the NE-induced up-regulation in both protein and
gene levels of VEGF, IL-8 and IL-6 was chiefly mediated
by β-AR/cAMP/PKA signaling pathway which had been
found to play a key role in mouse xenografts of melanoma
and ovarian cancer [9,17]. The stimulation of β-ARs by
neurotransmitters induces multiple signaling pathways of
which the most important one approved is cAMP/PKA/
CREB (cAMP response element binding protein). Then
the activation of CREB, a transcription factor, initiates
the arachidonic acid cascade, the Src/STAT and the
EGFR pathways followed by a wide variety of biological
effects [9,70].
Conclusions
Taken together, our data support the hypothesis that ex-
ogenous norepinephrine gives rise to the attenuation in theefficacy of sunitinib in a mouse melanoma model and pro-
vide a reason for the discrepancy of the efficacy of anti-
angiogenic drugs between clinical and preclinical results.
The combination of anti-angiogenic agents with β-AR
antagonists such as propranolol, a drug for cardio-
vascular disease for decades, might eliminate the in-
effectiveness of anti-angiogenic agents alone and enhance
their efficacy in some types of tumors, which has yet to
be approved in prospective randomized controlled trials
in clinic.
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